Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

54.8K
Overview
54.8K
Pneumonia IV: Management01:28

Pneumonia IV: Management

360
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
360
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

461
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
461
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

17
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
17
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

50
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
50
Biological Methods for Microbial Control01:28

Biological Methods for Microbial Control

64
Biological agents offer an effective means of controlling microbial growth by leveraging natural processes like predation, competition, and the secretion of antimicrobial substances.Predatory bacteria such as Bdellovibrio species target and kill pathogens like Salmonella and E. coli. They are widely used in poultry farms to control infections. Myxococcus species help combat plant-pathogenic fungi. These naturally occurring predators serve as eco-friendly alternatives to chemical pesticides and...
64

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Precision to Personalized: Catalyzing AI-Enabled Innovation in Drug Development.

Clinical and translational science·2026
Same author

A Large Cohort Study to Identify Risk Factors of Acute Kidney Injury in Pediatric Patients Undergoing Intravenous Vancomycin Therapy.

Pharmacotherapy·2025
Same author

Evaluating Tranexamic Acid Dosing Strategies for Postpartum Hemorrhage: A Population Pharmacokinetic Approach in Pregnant Individuals.

Journal of clinical pharmacology·2025
Same author

Exploration of the potential impact of batch-to-batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products.

CPT: pharmacometrics & systems pharmacology·2024
Same author

In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science.

Journal of pharmacokinetics and pharmacodynamics·2024
Same author

Perinatal Caffeine Administration Improves Outcomes in an Ovine Model of Neonatal Hypoxia-Ischemia.

Stroke·2024

Related Experiment Video

Updated: Jul 24, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.7K

Bayesian model-guided antimicrobial therapy in pediatrics.

Haden T Bunn1, Jogarao V S Gobburu1,2, Lindsey M Floryance1

  • 1Pumas-AI, Inc., Centreville, VA, United States.

Frontiers in Pharmacology
|July 10, 2023
PubMed
Summary

Optimizing antimicrobial dosing in children is difficult due to limited data. Bayesian-model informed precision dosing offers a solution to improve patient care and treatment outcomes.

Keywords:
antimicrobialsbayesianpediatricsprecision dosingtherapeutic drug monitoring

More Related Videos

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

2.0K
Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.1K

Related Experiment Videos

Last Updated: Jul 24, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.7K
Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

2.0K
Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.1K

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Clinical Decision Support

Background:

  • Antimicrobials are vital for treating infections, but optimal dosing, especially in pediatrics, is challenging.
  • Historically, limited pediatric clinical trials resulted in widespread off-label drug use.
  • Regulatory efforts like the Pediatric Research Equality Act aim to improve pediatric drug data, but progress is slow.

Purpose of the Study:

  • To describe challenges in pediatric antimicrobial dose optimization.
  • To present Bayesian-model informed precision dosing as a viable solution.
  • To encourage adoption of advanced pharmacotherapy strategies in clinical settings.

Main Methods:

  • Review of challenges in designing and implementing dose-optimization strategies.
  • Evidence synthesis supporting Bayesian-model informed precision dosing.
  • Discussion of integrated clinical decision support platforms.

Main Results:

  • Identified significant hurdles in pediatric antimicrobial dosing strategies.
  • Demonstrated the potential of Bayesian-model informed precision dosing to overcome these challenges.
  • Highlighted the increasing accessibility of model-informed precision dosing tools.

Conclusions:

  • Bayesian-model informed precision dosing addresses critical gaps in pediatric antimicrobial therapy.
  • Accessible clinical decision support platforms facilitate the implementation of precision dosing.
  • Clinicians are encouraged to champion these advanced pharmacotherapy techniques for improved patient outcomes.